Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Omeros Corporation (NASDAQ: OMER) | Delayed: 16.86 +0.60 (3.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.26 | 52 Week High | $16.80 | |||
| Open | $16.26 | 52 Week Low | $7.20 | |||
| Day High | $16.89 | P/E | N/A | |||
| Day Low | $16.15 | EPS | $-1.64 | |||
| Volume | 737,276 | |||||
